2. Academic Validation
  3. Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer

  • ACS Med Chem Lett. 2026 May 26;17(6):1246-1248. doi: 10.1021/acsmedchemlett.6c00256.
Anna C Renner 1,  Robert B Kargbo 2
Affiliations

Affiliations

  • 1 North Dakota State University, Fargo, North Dakota 58108-6050, United States.
  • 2 Independent Research Consultant, Middleton, Wisconsin 53562, United States.
PMID: 42305214 DOI: 10.1021/acsmedchemlett.6c00256
Abstract

Targeted protein degradation and biomarker-guided therapy offer complementary strategies for controlling transcription-driven cancers. One approach eliminates BCL6 through heterobifunctional degraders, while another defines S100A8/A9-centered biomarkers that predict response to BET inhibition. Together, they reveal how combining protein elimination with molecular stratification can overcome resistance, refine patient selection, and enable more durable therapeutic responses in oncology.

Figures
Products